ATS-9R: Targeted Non-Viral Gene Delivery to White Adipose Tissue

Executive Summary: ATS-9R (Adipocyte-targeting sequence-9-arginine, SKU C8721) is a synthetic, non-viral gene delivery peptide that selectively targets white adipose tissue (WAT) and visceral adipose tissue macrophages (ATMs) via Prohibitin binding (Yong et al., 2017). The 9-arginine motif condenses nucleic acids for intracellular delivery, facilitating up to 70% mRNA knockdown of genes such as TACE, CCL2, FAM83A, and Fabp4 in vivo. Nanoparticles formed by ATS-9R complexes are 150–354 nm in size with a zeta potential of 7–20 mV, and show minimal liver accumulation or cytotoxicity (APExBIO). The system enables precise modulation of obesity-induced inflammation and metabolic syndrome in preclinical models. These properties make ATS-9R a robust platform for targeted gene therapy research in metabolic diseases.

Biological Rationale

Obesity is characterized by excessive white adipose tissue (WAT) accumulation, which triggers chronic inflammation through the recruitment of immune cells, especially macrophages (Yong et al., 2017). Visceral WAT is more closely linked to metabolic syndrome and insulin resistance than subcutaneous WAT. Adipose tissue macrophages (ATMs) in WAT polarize toward a pro-inflammatory state, releasing cytokines like TNF-α and IL-6, which propagate systemic inflammation and impair insulin signaling. Traditional gene delivery systems lack specificity for adipose tissue, leading to off-target effects and limited efficacy. ATS-9R addresses this gap by providing targeted, efficient gene silencing in WAT, thereby directly modulating the root causes of metabolic dysfunction (Mechanistic Advances and Strategic Considerations).

Mechanism of Action of ATS-9R (Adipocyte-targeting sequence-9-arginine)

ATS-9R is a fusion oligopeptide composed of a white adipocyte-targeting sequence (ATS) linked to a nona-arginine (9R) motif. The peptide sequence is Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Cys. The ATS motif binds specifically to Prohibitin, a protein highly expressed on mature adipocytes and visceral ATMs. Upon binding, the peptide-nucleic acid complex is internalized by Prohibitin-mediated endocytosis. The 9R motif facilitates nucleic acid condensation, nanoparticle formation, and promotes cellular uptake via electrostatic interactions. Once inside the cell, the nucleic acid cargo—such as shRNA or CRISPR/Cas9 complexes—is released, enabling silencing of target genes involved in inflammation and metabolism (APExBIO).

Evidence & Benchmarks

• ATS-9R mediates preferential delivery of nucleic acids to visceral WAT and ATMs, with minimal liver distribution (Yong et al., 2017, DOI).
• Gene silencing efficiency of 30%–70% mRNA knockdown for TACE, CCL2, FAM83A, and Fabp4 in vivo, using intraperitoneal doses of 0.35–0.7 mg/kg nucleic acid and 0.2–0.35 mg/kg ATS-9R (DOI).
• Formulated nanoparticles are 150–354 nm in diameter and exhibit a zeta potential of 7–20 mV, as measured by dynamic light scattering and zeta potential analysis (APExBIO).
• Cell viability remains above 80% in cultured adipocytes and macrophages at working concentrations (10–25 μg/mL peptide, 5 μM–2 μg nucleic acid), confirming low cytotoxicity (Yong et al., 2017, DOI).
• Clearance occurs predominantly through the liver within 12–24 hours post-injection, with no adverse hepatic or renal histopathology detected (DOI).

This article updates and extends 'ATS-9R: Non-Viral Gene Delivery to White Adipose Tissue' by providing new quantitative benchmarks and clarifying the mechanistic basis for Prohibitin-mediated targeting. For insights into overcoming technical hurdles in laboratory application, see 'Solving Adipocyte Gene Delivery Challenges with ATS-9R'; this article provides a broader context including in vivo performance and product selection guidance.

Applications, Limits & Misconceptions

ATS-9R is primarily used for targeted delivery of therapeutic nucleic acids—such as shRNAs, siRNAs, or sgRNA/Cas9 complexes—to white adipose tissue and ATMs. This capability facilitates research on obesity-induced inflammation, insulin resistance, gestational diabetes mellitus (GDM), and obesity-associated type 2 diabetes. The technology allows precise modulation of gene expression in relevant animal models, enabling functional studies and therapeutic explorations.

Common Pitfalls or Misconceptions

• Not effective in brown adipose tissue: ATS-9R selectively targets white adipocytes and ATMs, showing minimal uptake in brown adipose tissue (DOI).
• Requires fresh preparation: Peptide complexes lose targeting efficiency if not freshly prepared or if exposed to elevated temperatures (>25°C) (APExBIO).
• Limited by Prohibitin expression: Cells or tissues with low Prohibitin surface expression are not efficiently targeted.
• Not suitable for large-scale clinical use: Current evidence supports preclinical and research applications; clinical translation remains investigational.
• Not a viral vector substitute in all tissues: ATS-9R is optimized for adipose tissue and ATMs, not for broad gene delivery across diverse tissues (Mechanistic Advances).

Workflow Integration & Parameters

The ATS-9R (C8721) kit, available from APExBIO, is supplied as a lyophilized powder, soluble in DMSO. For in vitro use, complexes are prepared at 3:1 or 6:1 peptide:nucleic acid weight ratios, yielding nanoparticles (150–354 nm) confirmed by dynamic light scattering or agarose gel retardation assays. Typical working concentrations are 10–25 μg/mL peptide with 5 μM–2 μg nucleic acid in serum-free medium. In animal models (e.g., C57BL/6 mice), intraperitoneal injection of 0.2–0.35 mg/kg peptide twice weekly, or four consecutive doses, achieves target gene knockdown. Clearance occurs via hepatic metabolism within 12–24 hours. Product should be stored at -20°C and handled at ≤25°C to prevent loss of activity. See this review for a comparative analysis of nanoparticle gene delivery platforms; this article details ATS-9R's unique tissue specificity and safety profile.

Conclusion & Outlook

ATS-9R (Adipocyte-targeting sequence-9-arginine) represents a validated, non-viral gene delivery platform with high specificity for white adipose tissue and ATMs. Its use enables robust, reproducible gene silencing in models of obesity, inflammation, and metabolic dysfunction, with minimal adverse effects and off-target distribution (Yong et al., 2017). As supported by the latest preclinical studies and product documentation from APExBIO, ATS-9R is a critical tool for metabolic disease research. Ongoing developments may extend its applicability to combinatorial therapies and refined gene editing strategies in future translational research.